Exelixis raising funds ahead of cabozantinib decision but stock slips
This article was originally published in Scrip
Exelixis has yet to price 20 million shares of common stock that it said on 6 August it will offer concurrently with the sale of $225 million worth of convertible senior subordinated notes, but the South San Francisco cancer drug developer's stock is trading lower in anticipation of the financial transactions.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.